Companies /Healthcare

GRAIL, LLC

NASDAQ: GRAL Diagnostics & Research
$105.60
▼ $10.29 (−8.88%) today
Markets closed · 4:26pm ET

24/7 Wall St. View

GRAL at a Glance

Valuation
Market cap
$5.2B
Profitability
Revenue (TTM)
$166.6M
Profit margin
-243.8%
EPS (TTM)
$-9.22
Price
52-week range
$42 – $166
24/7 target
$160.08
Street target
$139.44

Headquartered in Sunnyvale, CA Fiscal year ends December NASDAQ: GRAL grail.com

About Grail

GRAIL, Inc. is a healthcare company focused on detecting cancer early, when it can be cured. Its flagship product, the Galleri multi-cancer early detection blood test, uses next-generation sequencing, a targeted methylation-based platform and machine learning. The test identifies cancer-shed DNA and can indicate the cancer's tissue of origin. It screens for many cancers that lack recommended screening today, such as pancreatic, esophageal, ovarian and liver cancer. Galleri requires a prescription and is intended for adults at elevated risk, such as those aged 50 or older, as a complement to standard screenings. It is currently offered as a laboratory-developed test through GRAIL's CLIA-certified, CAP-accredited lab and is not yet FDA-approved. In September 2026, an FDA Advisory Committee voted in favor of approval, with an FDA decision anticipated by early Q1 2027. GRAIL earns screening revenue from Galleri tests and development services revenue from biopharma and other partners. Its platform also supports precision oncology applications, including detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, and treatment and recurrence monitoring. The company has a commercial relationship with Samsung under a stock purchase agreement, and its stock trades on Nasdaq under GRAL. Updated

Latest Activity

GRALGrail
Q3 2026
EPS
-$2.21
est -$1.90-16.4%
Revenue
$38M
est $44M-15.1%

A double miss on earnings and revenue barely matters next to the FDA decision on Galleri expected by early Q1 2027, which would open the door to broad reimbursement. Galleri screening revenue still grew 14% in the meantime.

Quarterly EPS — reported vs estimate

GRAL Coverage

Frequently Asked Questions

What does Grail do?

GRAIL, Inc. is a healthcare company focused on detecting cancer early, when it can be cured. Its flagship product, the Galleri multi-cancer early detection blood test, uses next-generation sequencing, a targeted methylation-based platform and machine learning.

What is the GRAL stock price target?

24/7 Wall St.'s 12-month price target for GRAL is $160.08, rated Buy. The Wall Street consensus target is $139.44. GRAL price prediction →